Preimplantation Genetic Testing
- 1 March 2020
- journal article
- editorial
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 135 (3) , e133-e137
Abstract
Preimplantation genetic testing comprises a group of genetic assays used to evaluate embryos before transfer to the uterus. Preimplantation genetic testing-monogenic is targeted to single gene disorders, and preimplantation genetic testing-aneuploidy is a broader test that screens for aneuploidy in all chromosomes, including the 22 pairs of autosomes and the sex chromosomes X and Y. To test embryos that are at risk for chromosome gains and losses related to parental structural chromosomal abnormalities (eg, translocations, inversions, deletions, and insertions), preimplantation genetic testing-structural rearrangements is used. Independent of the preimplantation genetic testing modality employed, false-positive and false-negative results are possible. Patients and health care providers should be aware that a “normal” or negative preimplantation genetic test result is not a guarantee of a newborn without genetic abnormalities. Traditional diagnostic testing or screening for aneuploidy should be offered to all patients who have had preimplantation genetic testing-aneuploidy, in accordance with recommendations for all pregnant patients. It is especially important to offer diagnostic testing or screening for aneuploidy after preimplantation genetic testing-monogenic or preimplantation genetic testing-structural rearrangements if concurrent preimplantation genetic testing-aneuploidy is not performed. Many limitations exist to preimplantation genetic testing and include challenges in detecting microdeletions and microduplications, de novo variants, and imprinting disorders. An emerging problem has been detection of mosaicism during preimplantation genetic testing-aneuploidy. The clinical utility of preimplantation genetic testing-monogenic and preimplantation genetic testing-structural rearrangements is firmly established; however, the best use of preimplantation genetic testing-aneuploidy remains to be determined. Future research is necessary to establish the overall clinical utility for preimplantation genetic testing-aneuploidy, the subset of patients that may benefit from preimplantation genetic testing-aneuploidy, the clinical significance of mosaicism, and residual risk for aneuploidy in preimplantation genetic testing-aneuploidy screened embryos.Keywords
This publication has 22 references indexed in Scilit:
- Practice Bulletin No. 162Obstetrics & Gynecology, 2016
- Post-thaw ATP supplementation enhances cryoprotective effect of iodixanol in rat spermatozoaReproductive Biology and Endocrinology, 2016
- Healthy Babies after Intrauterine Transfer of Mosaic Aneuploid BlastocystsNew England Journal of Medicine, 2015
- Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo selection: pre- and post-intervention studyHuman Reproduction, 2015
- The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic reviewHuman Reproduction, 2014
- Cleavage-stage biopsy significantly impairs human embryonic implantation potential while blastocyst biopsy does not: a randomized and paired clinical trialFertility and Sterility, 2013
- What next for preimplantation genetic screening (PGS)? A position statement from the ESHRE PGD Consortium steering committeeHuman Reproduction, 2010
- ACOG Committee Opinion No. 410: Ethical Issues in Genetic TestingObstetrics & Gynecology, 2008
- In Vitro Fertilization with Preimplantation Genetic ScreeningNew England Journal of Medicine, 2007
- Preimplantation HLA typing: having children to save our loved onesJournal of Medical Ethics, 2005